Shoji Nakamori

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

Katsuhiko Uesaka, Narikazu Boku, Akira Fukutomi et al. · The Lancet · 2016 · 1.1K citations

Medicine, Oncology, Chemotherapy +7

Randomized clinical trial of adjuvant gemcitabine chemotherapy <i>versus</i> observation in resected bile duct cancer

Tomoki Ebata, Satoshi Hirano, Masaru Konishi et al. · British journal of surgery · 2018 · 395 citations

Medicine, Oncology, Cancer Control +12

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Chigusa Morizane, Takuji Okusaka, Junki Mizusawa et al. · Annals of Oncology · 2019 · 334 citations

Medicine, Oncology, Chemotherapy +7

MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma

Shoji Nakamori, David M. Ota, Karen R. Cleary et al. · Gastroenterology · 1994 · 282 citations · Full text

Medicine, Oncology, Pathology +12

Genetic diagnosis of lymph-node metastasis in colorectal cancer

N. Hayashi, Isao Ito, Yusuke Nakamura et al. · The Lancet · 1995 · 280 citations

Medicine, Genetics, Oncology +16